Current status of antifungal susceptibility testing methods

Medical Mycology

Volumn 45, Issue 7, 2007, Pages 569-587

  Arikan, Sevtap ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antifungal susceptibility; Disk diffusion; Ergosterol quantitation; Etest; Flow cytometry; Microdilution

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANALYTIC METHOD; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; COLORIMETRY; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DIFFUSION; DILUTION; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUSARIUM; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; INCUBATION TIME; INTERMETHOD COMPARISON; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOLOGY; NONHUMAN; PETRIELLIDIUM BOYDII; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REPRODUCIBILITY; REVIEW; RHIZOPUS; SPOROTHRIX SCHENCKII; STANDARDIZATION; TREATMENT OUTCOME;

AGAR; ANTIFUNGAL AGENTS; CALORIMETRY; CANDIDA; ERGOSTEROL; FLOW CYTOMETRY; FUNGI; MICROBIAL SENSITIVITY TESTS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

CANDIDA; FUNGI;

EID: 36549061593     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780701436794     Document Type: Review

References (203)

1. Nucci, M. and Marr, KA (2005) Emerging fungal diseases. Clin Infect Dis, 41, pp. 521-526.
2. Bodey, GP (1988) The emergence of fungi as major hospital pathogens. J Hosp Infect, 11, pp. 411-426.
3. Alexander, BD and Perfect, JR (1997) Antifungal resistance trends towards the year 2000: Implications for therapy and new approaches. Drugs, 54, pp. 657-678.
4. Moore, CB, Sayers, N., Mosquera, J., Slaven, J. and Denning, DW (2000) Antifungal drug resistance in Aspergillus. J Infec, 41, pp. 203-220.
5. Muller, FMC, Weig, M., Peter, J. and Walsh, TJ (2000) Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother, 46, pp. 338-340.
6. Canuto, M Masia and Rodero, F Gutierrez (2002) Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis, 2, pp. 550-563.
7. Kontoyiannis, DP and Lewis, RE (2002) Antifungal drug resistance of pathogenic fungi. Lancet, 359, pp. 1135-1144.
8. Loeffler, J. and Stevens, DA (2003) Antifungal drug resistance. Clin Infect Dis, 36, pp. S31-S41.
9. Bille, J., Marchetti, O. and Calandra, T. (2005) Changing face of health-care associated fungal infections. Curr Opin Infect Dis, 18, pp. 314-319.
10. Arikan, S. and Rex, JH (2005) Resistance to antifungal agents. Topley & Wilson's Microbiology and Microbial Infections-Medical Mycology, pp. 168-181. Hodder Arnold Publishing, London
11. National Committee for Clinical Laboratory Standards (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard NCCLS Document M27-A2, National Committee for Clinical Laboratory Standards, Wayne, PA
12. National Committee for Clinical Laboratory Standards (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard NCCLS Document M38-A, National Committee for Clinical Laboratory Standards, Wayne, PA
13. Swinne, D., Watelle, M., Van der Flaes, M. and Nolard, N. (2004) In vitro activities of voriconazole (UK-109,496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses, 47, pp. 177-183.
14. Lozano-Chiu, M., Arikan, S., Paetznick, VL, Anaissie, EJ and Rex, JH (1999) Optimizing voriconazole susceptibility testing of Candida: Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J Clin Microbiol, 37, pp. 2755-2759.
15. Dannaoui, E., Meletiadis, J., Mouton, JW, Meis, J. and Verweij, PE (2003) In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother, 51, pp. 45-52.
16. Meletiadis, J., Mouton, JW and Meis, JFG (2001) Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol, 39, pp. 4256-4263.
17. Pfaller, MA, Diekema, DJ and Rex, JH (2006) Correlation of MIC with outcome for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J Clin Microbiol, 44, pp. 819-826.
18. Pfaller, MA, Diekema, DJ and Rinaldi, MG (2005) Results from the ARTEMIS DISK global antifungal surveillance study: A 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol, 43, pp. 5848-5859.
19. Pfaller, MA, Boyken, L., Messer, SA, Hollis, RJ and Diekema, DJ (2004) Stability of Mueller-Hinton agar supplemented with glucose and methylene blue for disk diffusion testing of fluconazole and voriconazole. J Clin Microbiol, 42, pp. 1288-1289.
20. Hazen, KC, Baron, EJ and Colombo, AL (2003) Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol, 41, pp. 5623-5632.
21. National Committee for Clinical Laboratory Standards (2004) Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline M44-A, National Committee for Clinical Laboratory Standards, Wayne, PA
22. Rubio, MC, Gil, J., de Ocariz, IR, Benito, R. and Rezusta, A. (2003) Comparison of results obtained by testing with three different agar media and by the NCCLS M27-A method for in vitro testing of fluconazole against Candida spp. J Clin Microbiol, 41, pp. 2665-2668.
23. Sims, CR, Paetznick, VL, Rodriguez, JR, Chen, E. and Ostrosky-Zeichner, L. (2006) Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol, 44, pp. 2105-2108.
24. Barry, AL, Pfaller, MA, Rennie, RP, Fuchs, PC and Brown, SD (2002) Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother, 46, pp. 1781-1784.
25. Ergin, A. and Arikan, S. (2002) Comparison of microdilution and disc diffusion methods in assessing the in vitro activity of fluconazole and Melaleuca alternifolia (tea tree) oil against vaginal Candida isolates. J Chemother, 14, pp. 465-472.
26. Matar, MJ, Ostrosky-Zeichner, L. and Paetznick, VL (2003) Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother, 47, pp. 1647-1651.
27. Lopez-Oviedo, E., Aller, AI and Martin, C. (2006) Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: Comparison with CLSI broth microdilution method. Antimicrob Agents Chemother, 50, pp. 1108-1111.
28. Arikan, S., Yurdakul, P. and Hascelik, G. (2003) Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother, 47, pp. 2640-2643.
29. Arikan, S., Paetznick, V. and Rex, JH (2002) Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother, 46, pp. 3084-3087.
30. Pfaller, MA, Messer, SA and Boyken, L. (2004) Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol, 42, pp. 3117-3119.
31. Arikan, S. and Hascelik, G. (2002) Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis, 43, pp. 107-111.
32. Paphitou, NI, Ostrosky-Zeichner, L. and Paetznick, VL (2002) In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother, 46, pp. 1144-1146.
33. Fernandez-Torres, B., Carrillo-Munoz, A., Inza, I. and Guarro, J. (2006) Effect of culture medium on the disk diffusion method for determining antifungal susceptibilities of dermatophytes. Antimicrob Agents Chemother, 50, pp. 2222-2224.
34. Santos, DA and Hamdan, JS (2005) Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum. J Clin Microbiol, 43, pp. 1917-1920.
35. Cordeiro, RA, Brilhante, RSN and Rocha, MFG (2006) In vitro activities of caspofungin, amphotericin B and azoles against Coccidioides posadasii strains from Northeast, Brazil. Mycopathologia, 161, pp. 21-26.
36. Diekema, DJ, Petroelje, B., Messer, SA, Hollis, RJ and Pfaller, MA (2005) Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol, 43, pp. 476-478.
37. Espinel-Ingroff, A., Chaturvedi, V., Fothergill, A. and Rinaldi, MG (2002) Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol, 40, pp. 3776-3781.
38. Ryder, NS (1999) Activity of terbinafine against serious fungal pathogens. Mycoses, 42, pp. 115-119.
39. Girmenia, C., Pizzarelli, G., D'Antonio, D., Cristini, F. and Martino, P. (2003) In vitro susceptibility testing of Geotrichum capitatum: Comparison of the E-test, disk diffusion, and sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother, 47, pp. 3985-3988.
40. Pfaller, MA, Boyken, L. and Hollis, RJ (2006) In vitro susceptibilities of Candida spp. to caspofungin: Four years of global surveillance. J Clin Microbiol, 44, pp. 760-763.
41. Messer, SA, Diekema, DJ and Boyken, L. (2006) Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol, 44, pp. 324-326.
42. Pfaller, MA, Boyken, L. and Hollis, RJ (2005) In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol, 43, pp. 5425-5427.
43. Odds, FC, Motyl, M. and Andrade, R. (2004) Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol, 42, pp. 3475-3482.
44. Arikan, S., Lozano-Chiu, M., Paetznick, V. and Rex, JH (2001) In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother, 45, pp. 327-330.
45. Kurtz, MB and Douglas, CM (1997) Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol, 35, pp. 79-86.
46. Messer, SA, Kirby, JT, Sader, HS, Fritsche, TR and Jones, RN (2004) Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother, 54, pp. 1051-1056.
47. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing, Rodriguez-Tudela, JL and Barchiesi, F. (2002) European Society for Clinical Microbiology and Infectious Diseases, European Society for Clinical Microbiology and Infectious Diseases, Munich, Germany
48. Cuenca-Estrella, M., Moore, CB and Barchiesi, F. (2003) Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect, 9, pp. 467-474.
49. Espinel-Ingroff, A., Barchiesi, F. and Cuenca-Estrella, M. (2005) International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol, 43, pp. 3884-3889.
50. Cuenca-Estrella, M., Lee-Yang, W. and Ciblak, MA (2002) Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother, 46, pp. 3644-3647.
51. Lass-Florl, C., Cuenca-Estrella, M., Denning, DW and Rodriguez-Tudela, JL (2006) Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med Mycol, 44, pp. S319-S325.
52. Chryssanthou, E. and Cuenca-Estrella, M. (2006) Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin Microbiol Infect, 12, pp. 901-904.
53. Arthington-Skaggs, BA, Lee-Yang, W. and Ciblak, MA (2002) Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother, 46, pp. 2477-2481.
54. Liao, RS, Rennie, RP and Talbot, JA (2001) Novel fluorescent broth microdilution method for fluconazole susceptibility testing of Candida albicans. J Clin Microbiol, 39, pp. 2708-2712.
55. Ostrosky-Zeichner, L., Rex, JH and Pappas, PG (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother, 47, pp. 3149-3154.
56. Rex, JH, Nelson, PW and Paetznick, VL (1998) Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother, 42, pp. 129-134.
57. Marr, KA, Rustad, TR, Rex, JH and White, TC (1999) The trailing endpoint phenotype in antifungal susceptibility testing is pH-dependent. Antimicrob Agents Chemother, 43, pp. 1383-1386.
58. Pfaller, MA, Messer, SA, Mills, K., Bolmstrom, A. and Jones, RN (2001) Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. J Clin Microbiol, 39, pp. 3952-3954.
59. Stevens, DA, White, TC, Perlin, DS and Selitrennikoff, CP (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis, 51, pp. 173-178.
60. Clemons, KV, Espiritu, M., Parmar, R. and Stevens, DA (2006) Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother, 50, pp. 1293-1297.
61. Stevens, DA, Ichinomiya, M., Koshi, Y. and Horiuchi, H. (2006) Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother, 50, pp. 3160-3161.
62. Arikan, S., Sancak, B. and Hascelik, G. (2005) In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol, 43, pp. 171-178.
63. St-Germain, G. (1990) Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans. Antimicrob Agents Chemother, 34, pp. 2304-2306.
64. Wong-Beringer, A., Hindler, J., Brankovic, L., Muehlbauer, L. and Steele-Moore, L. (2001) Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients. Diagn Microbiol Infect Dis, 39, pp. 25-31.
65. Rex, JH and Pfaller, MA (2002) Has antifungal susceptibility testing come of age?. Clin Infect Dis, 35, pp. 982-989.
66. Hospenthal, DR, Murray, CK and Rinaldi, MG (2004) The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis, 48, pp. 153-160.
67. Reyes, G. and Ghannoum, MA (2000) Antifungal susceptibility testing of yeasts: Uses and limitations. Drug Resist Update, 3, pp. 14-19.
68. Espinel-Ingroff, A. (2003) Utility of mould susceptibility testing. Curr Opin Infect Dis, 16, pp. 527-532.
69. Dromer, F., Improvisi, L., Dupont, B. and Loebenberg, D. (2002) In vitro and in vivo activity of SCH-56592 (posaconazole) against Aspergillus fumigatus. J Mycologie Medicale, 12, pp. 52-57.
70. Nguyen, MH, Clancy, CJ and Yu, VL (1998) Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect. Dis, 177, pp. 425-430.
71. Rex, JH, Cooper Jr, CR., Merz, WG, Galgiani, JN and Anaissie, EJ (1995) Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother, 39, pp. 906-909.
72. Lozano-Chiu, M., Nelson, PW, Lancaster, M., Pfaller, MA and Rex, JH (1997) Lot-to-lot variability of antibiotic medium 3 when used for susceptibility testing of Candida isolates to amphotericin B. J Clin Microbiol, 35, pp. 270-272.
73. Wanger, A., Mills, K., Nelson, PW and Rex, JH (1995) Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother, 39, pp. 2520-2522.
74. Clancy, CJ and Nguyen, MH (1999) Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother, 43, pp. 1289-1290.
75. Peyron, F., Favel, A. and Michel-Nguyen, A. (2001) Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol, 39, pp. 339-342.
76. Park, BJ, Arthington-Skaggs, BA and Hajjeh, RA (2006) Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother, 50, pp. 1287-1292.
77. Huang, YC, Kao, HT, Lin, TY and Kuo, AJ (2001) Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. Amer J Perinatol, 18, pp. 141-146.
78. Lionakis, MS, Lewis, RE, Chamilos, G. and Kontoyiannis, DP (2005) Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: Difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy, 25, pp. 1174-1180.
79. Mosquera, J., Warn, PA and Morrissey, J. (2001) Susceptibility testing of Aspergillus flavus: Inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother, 45, pp. 1456-1462.
80. Dannaoui, E., Abdul, M. and Arpin, M. (2006) Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother, 50, pp. 2464-2470.
81. Anaissie, E., Paetznick, V., Proffitt, R., Adler, MJ and Bodey, GP (1991) Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis, 10, pp. 665-668.
82. Pahls, S. and Schaffner, A. (1994) Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candiasis. J Infect Dis, 169, pp. 1057-1061.
83. Oakley, KL, Moore, CB and Denning, DW (1999) Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother, 43, pp. 1264-1266.
84. Pfaller, MA, Diekema, DJ and Sheehan, DJ (2006) Interpretive breakpoints for fluconazole and Candida revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev, 19, pp. 435-447.
85. Denning, DW, Radford, SA and Oakley, KL (1997) Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother, 40, pp. 401-414.
86. Denning, DW, Venkateswarlu, K. and Oakley, KL (1997) Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother, 41, pp. 1364-1368.
87. Chryssanthou, E. and Cuenca-Estrella, M. (2002) Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol, 40, pp. 3841-3844.
88. Betts, R., Glasmacher, A. and Maertens, J. (2006) Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer, 106, pp. 466-473.
89. Hakki, M., Staab, JF and Marr, MA (2006) Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother, 50, pp. 2522-2524.
90. Hernandez, S., Lopez-Ribot, JL and Najvar, LK (2004) Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother, 48, pp. 1382-1383.
91. Laverdiere, M., Lalonde, RG and Baril, JG (2006) Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother, 57, pp. 705-708.
92. Kartsonis, N., Killar, J. and Mixson, L. (2005) Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: Relationship of MIC to treatment outcome. Antimicrob Agents Chemother, 49, pp. 3616-3623.
93. Park, S., Kelly, R. and Kahn, JN (2005) Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob Agents Chemother, 49, pp. 3264-3273.
94. Favel, A., Chastin, C. and Thomet, AL (2000) Evaluation of the E test for antifungal susceptibility testing of Candida glabrata. Eur J Clin Microbiol Infect Dis, 19, pp. 146-148.
95. Pfaller, MA, Messer, SA, Mills, K., Bolmstrom, A. and Jones, RN (2001) Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol, 39, pp. 4387-4389.
96. Pfaller, MA, Messer, SA, Mills, K. and Bolmstrom, A. (2000) In vitro susceptibility testing of filamentous fungi: Comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol, 38, pp. 3359-3361.
97. Pfaller, MA, Messer, SA and Houston, A. (2000) Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol, 38, pp. 3715-3717.
98. Petrou, MA and Shanson, DC (2000) Susceptibility of Cryptococcus neoformans by the NCCLS microdilution and Etest methods using five defined media. J Antimicrob Chemother, 46, pp. 815-818.
99. Lozano-Chiu, M., Paetznick, VL, Ghannoum, MA and Rex, JH (1998) Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: Performance of three different media assessed by using E-Test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin. Microbiol, 36, pp. 2817-2822.
100. Favel, A., Peyron, F. and De Meo, M. (1999) Amphotericin B susceptibility testing of Candida lusitaniae isolates by flow cytofluorometry: Comparison with the Etest and the NCCLS broth macrodilution method. J Antimicrob Chemother, 43, pp. 227-232.
101. Pfaller, MA, Boyken, L. and Messer, SA (2004) Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol, 42, pp. 4977-4979.
102. Pfaller, MA, Diekema, DJ and Boyken, L. (2003) Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol, 41, pp. 1875-1880.
103. Maxwell, MJ, Messer, SA and Hollis, RJ (2003) Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol, 41, pp. 1087-1090.
104. Maxwell, AJ, Messer, SA, Hollis, RJ, Diekema, DJ and Pfaller, MA (2003) Evaluation of etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans. J Clin Microbiol, 41, pp. 97-99.
105. Pfaller, JB, Messer, SA, Hollis, RJ, Diekema, DJ and Pfaller, MA (2003) In vitro susceptibility testing of Aspergillus spp.: Comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol, 41, pp. 1126-1129.
106. Pfaller, MA, Messer, SA, Boyken, L., Hollis, RJ and Diekema, DJ (2003) In vitro susceptibility testing of filamentous fungi: Comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis, 45, pp. 241-244.
107. Espinel-Ingroff, A. (2001) Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol, 39, pp. 1360-1367.
108. Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E. and Rodriguez-Tudela, JL (2005) Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect, 11, pp. 486-492.
109. Pfaller, MA, Arikan, S. and Lozano-Chiu, M. (1998) Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing. J Clin Microbiol, 36, pp. 2609-2612.
110. Bernal, S., Aller, AI and Chavez, M. (2002) Comparison of the Sensititre YeastOne colorimetric microdilution panel and the NCCLS broth microdilution method for antifungal susceptibility testing against Candida species. Chemotherapy, 48, pp. 21-25.
111. Pfaller, MA, Espinel-Ingroff, A. and Jones, RN (2004) Clinical evaluation of the sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol, 42, pp. 4577-4580.
112. Carrillo-Munoz, AJ, Quindos, G. and Ruesga, M. (2006) In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One. Mycoses, 49, pp. 293-297.
113. Carrillo-Munoz, AJ, Quindos, G., Valle, O Del, Hernandez-Molina, JM and Santos, P. (2004) Antifungal activity of amphotericin B and itraconazole against filamentous fungi: Comparison of the Sensititire Yeast One and NCCLS M38-A reference methods. J Chemotherapy, 16, pp. 468-473.
114. Pujol, I., Capilla, J., Fernandez-Torres, B., Ortoneda, M. and Guarro, J. (2002) Use of the sensititre colorimetric microdilution panel for antifungal susceptibility testing of dermatophytes. J Clin Microbiol, 40, pp. 2618-2621.
115. Davey, KG, Szekely, A., Johnson, EM and Warnock, DW (1998) Comparison of a new commercial colorimetric microdilution method with a standard method for in vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother, 42, pp. 439-444.
116. Hawser, SP, Norris, H., Jessup, CJ and Ghannoum, MA (1998) Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H- tetrazolium hydroxide (XTT) colorimetric method with the Standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol, 36, pp. 1450-1452.
117. Meletiadis, J., Mouton, JW and Meis, JF (2001) Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol, 39, pp. 3402-3408.
118. Meletiadis, J., Mouton, JW and Meis, JF (2001) Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-Bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol, 39, pp. 4256-4263.
119. Hawser, SP, Jessup, C., Vitullo, J. and Ghannoum, MA (2001) Utility of
120. Antachopoulos, C., Meletiadis, J., Roilides, E., Sein, T. and Walsh, TJ (2006) Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol, 44, pp. 553-560.
121. Menon, T., Umamaheswari, K., Kumarasamy, N., Solomon, S. and Thyagarajan, SP (2001) Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients. Acta Trop, 80, pp. 151-154.
122. Barchiesi, F., Tortorano, AM and Francesco, LF Di (1999) In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J Antimicrob Chemother, 43, pp. 295-299.
123. Kirkpatrick, WR, McAtee, RK and Revankar, SG (1998) Comparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of Cryptococcus neoformans. J Clin Microbiol, 36, pp. 1330-1332.
124. Verweij, PE, Mensink, M. and Rijs, A. (1998) In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother, 42, pp. 389-392.
125. Imhof, A., Balajee, SA and Marr, KA (2003) New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol, 41, pp. 5683-5688.
126. Mock, M., Monod, M., Baudraz-Rosselet, F. and Panizzon, RG (1998) Tinea capitis dermatophytes: Susceptibility to antifungal drugs tested in vitro and in vivo. Dermatology, 197, pp. 361-367.
127. Speeleveld, E., Gordts, B., Van Landuyt, HW, De Vroey, C. and Raes-Wuytack, C. (1996) Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses, 39, pp. 37-40.
128. Hammer, KA, Carson, CF and Riley, TV (2000) In vitro activities of ketoconazole, econazole, miconazole, and Melaleuca alternifolia (Tea tree) oil against Malassezia species. Antimicrob Agents Chemother, 44, pp. 467-469.
129. Sancak, B., Ayhan, M., Karaduman, A. and Arikan, S. (2005) In vitro activity of ketoconazole, itraconazole and terbinafine against Malassezia strains isolated from neonates [Article in Turkish]. Mikrobiyol Bul, 39, pp. 301-308.
130. Pfaller, MA, Sheehan, DJ and Rex, JH (2004) Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev, 17, pp. 268-280.
131. Canton, E., Peman, J. and Viudes, A. (2003) Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis, 45, pp. 203-206.
132. Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, MG and Walsh, TJ (2002) Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS Collaborative Study. J Clin Microbiol, 40, pp. 3204-3208.
133. Rubio, MC, de Ocariz, IR, Gil, J., Benito, R. and Rezusta, A. (2005) Potential fungicidal effect of voriconazole against Candida spp. Int J Antimicrobial Agents, 25, pp. 264-267.
134. Canton, E., Peman, J., Sastre, M., Romero, M. and Espinel-Ingroff, A. (2006) Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother, 50, pp. 2829-2832.
135. Clancy, CJ, Huang, H., Cheng, SJ, Derendorf, H. and Nguyen, MH (2006) Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother, 50, pp. 2569-2572.
136. Takemoto, K., Yamamoto, Y. and Ueda, Y. (2006) Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Microbiol Immunol, 50, pp. 579-586.
137. Barchiesi, F., Spreghini, E. and Tomassetti, S. (2005) Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother, 49, pp. 4989-4992.
138. Canton, E., Peman, J., Gobernado, M., Viudes, A. and Espinel-Ingroff, A. (2004) Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother, 48, pp. 2477-2482.
139. Bonaventura, G Di, Spedicato, I., Picciani, C., D'Antonio, D. and Piccolomini, R. (2004) In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother, 48, pp. 4453-4456.
140. Ernst, EJ, Roling, EE, Petzold, CR, Keele, DJ and Klepser, ME (2002) In vitro activity of micafungin (FK-463) against Candida spp.: Microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother, 46, pp. 3846-3853.
141. Burgess, DS, Hastings, RW, Summers, KK, Hardin, TC and Rinaldi, MG (2000) Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn Microbiol Infect Dis, 36, pp. 13-18.
142. Lewis, RE, Klepser, ME and Pfaller, MA (2000) In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis, 36, pp. 101-105.
143. Klepser, ME, Malone, D., Lewis, RE, Ernst, EJ and Pfaller, MA (2000)
144. van Duin, D., Cleare, W., Zaragoza, O., Casadevall, A. and Nosanchuk, JD (2004) Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother, 48, pp. 2014-2020.
145. Klepser, ME, Ernst, EJ, Lewis, RE, Ernst, ME and Pfaller, MA (1998) Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods. Antimicrob Agents Chemother, 42, pp. 1207-1212.
146. Ernst, EJ, Klepser, ME and Pfaller, MA (2000) Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother, 44, pp. 1108-1111.
147. Manavathu, EK, Cutright, JL and Chandrasekar, PH (1998) Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother, 42, pp. 3018-3021.
148. Manavathu, EK, Ramesh, MS, Baskaran, I., Ganesan, LT and Chandrasekar, PH (2004) A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother, 53, pp. 386-389.
149. Vale-Silva, LA and Buchta, V. (2006) Antifungal susceptibility testing by flow cytometry: Is it the future?. Mycoses, 49, pp. 261-273.
150. Rudensky, B., Broidie, E. and Yinnon, AM (2005) Rapid flow-cytometric susceptibility testing of Candida species. J Antimicrob Chemother, 55, pp. 106-109.
151. Balajee, SA and Marr, KA (2002) Conidial viability assay for rapid susceptibility testing of Aspergillus species. J Clin Microbiol, 40, pp. 2741-2745.
152. Wenisch, C., Moore, CB and Krause, R. (2001) Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol, 39, pp. 2458-2462.
153. Ramani, R. and Chaturvedi, V. (2000) Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. Antimicrob Agents Chemother, 44, pp. 2752-2758.
154. Mitchell, M., Hudspeth, M. and Wright, A. (2005) Flow cytometry susceptibility testing for the antifungal caspofungin. J Clin Microbiol, 43, pp. 2586-2589.
155. Chaturvedi, V., Ramani, R. and Pfaller, MA (2004) Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans. J Clin Microbiol, 42, pp. 2249-2251.
156. Pina-Vaz, C., Sansonetty, F. and Rodrigues, AG (2001) Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy. J Med Microbiol, 50, pp. 375-382.
157. Pina-Vaz, C., Sansonetty, F. and Rodrigues, AG (2001) Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect, 7, pp. 609-618.
158. Ramani, R., Gangwar, M. and Chaturvedi, V. (2003) Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-a-vis amphotericin B and itraconazole. Antimicrob Agents Chemother, 47, pp. 3627-3629.
159. Arthington-Skaggs, BA, Jradi, H., Desai, T. and Morrison, CJ (1999) Quantitation of ergosterol content: Novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol, 37, pp. 3332-3337.
160. Arthington-Skaggs, BA, Warnock, DW and Morrison, CJ (2000) Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother, 44, pp. 2081-2085.
161. Lewis, RE (2006) Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy, 26:6, p. 61S.
162. Dannaoui, E., Lortholary, O. and Dromer, F. (2003) Methods for antifungal combination studies in vitro and in vivo in animal models. J Mycologie Medicale, 13, pp. 73-85.
163. Karlowsky, JA, Hoban, DJ, Zhanel, GG and Goldstein, BP (2006) In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrobial Agents, 27, pp. 174-177.
164. Cuenca-Estrella, M., Gomez-Lopez, A. and Buitrago, MJ (2006) In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother, 50, pp. 2248-2250.
165. Kirkpatrick, WR, Coco, BJ and Patterson, TF (2006) Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother, 50, pp. 1567-1569.
166. Cacciapuoti, A., Halpern, J. and Mendrick, C. (2006) Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother, 50, pp. 2587-2590.
167. Clemons, KV and Stevens, DA (2006) Animal models testing monotherapy versus combination antifungal therapy: Lessons learned and future directions. Curr Opin Infect Dis, 19, pp. 360-364.
168. Meletiadis, J., Petraitis, V. and Petraitiene, R. (2006) Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: In vitro and in vivo correlation. J Infec Dis, 194, pp. 1008-1018.
169. O'Shaughnessy, EM, Meletiadis, J., Stergiopoulou, T., Demchok, JP and Walsh, TJ (2006) Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother, 58, pp. 1168-1176.
170. Spellberg, B., Edwards Jr, JE. and Ibrahim, AS (2005) Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother, 49, pp. 830-832.
171. Cuenca-Estrella, M., Gomez-Lopez, A. and Garcia-Effron, G. (2005) Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother, 49, pp. 1232-1235.
172. Barchiesi, F., Spreghini, E. and Fothergill, AW (2005) Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother, 49, pp. 2546-2549.
173. Serena, C., Fernandez-Torres, B. and Pastor, FJ (2005) In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother, 49, pp. 2994-2996.
174. Oliveira, ER, Fothergill, AW and Kirkpatrick, WR (2005) In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother, 49, pp. 3544-3545.
175. Philip, A., Odabasi, Z. and Rodriguez, J. (2005) In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother, 49, pp. 3572-3574.
176. Clemons, KV, Espiritu, M., Parmar, R. and Stevens, DA (2005) Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother, 49, pp. 4867-4875.
177. Dannaoui, E., Lortholary, O. and Dromer, F. (2004) In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother, 48, pp. 970-978.
178. Steinbach, WJ, Schell, WA and Blankenship, JR (2004) In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother, 48, pp. 1664-1669.
179. Meletiadis, J., Mouton, JW, Meis, J. and Verweij, PE (2003) In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedospotium prolificans isolates. Antimicrob Agents Chemother, 47, pp. 106-117.
180. Arikan, S., Lozano-Chiu, M., Paetznick, V. and Rex, JH (2002) In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother, 46, pp. 245-247.
181. Odds, FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother, 52, p. 1.
182. Velasquez, S., Bailey, E. and Jandourek, A. (2000) Evaluation of the antifungal activity of Amphotericin B in combination with fluconazole, itraconazole, voriconazole or posaconazole against Candida species using a checkerboard method. Clin Infect Dis, 31, p. 266.
183. Mukherjee, PK, Sheehan, DJ, Hitchcock, CA and Ghannoum, MA (2005) Combination treatment of invasive fungal infections. Clin Microbiol Rev, 18, pp. 163-194.
184. Canton, E., Peman, J., Gobernado, M., Viudes, A. and Espinel-Ingroff, A. (2005) Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother, 49, pp. 1593-1596.
185. Lewis, RE, Diekema, DJ, Messer, SA, Pfaller, MA and Klepser, ME (2002) Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother, 49, pp. 345-351.
186. Hope, WW, Warn, PA and Sharp, A. (2005) Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. J Infec Dis, 192, pp. 673-680.
187. Dorsthorst, DT Te, Verweij, PE, Meis, J., Punt, NC and Mouton, JW (2004) In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Chemother, 48, pp. 2007-2013.
188. Meletiadis, J., Verweij, PE, Dorsthorst, DT Te, Meis, J. and Mouton, JW (2005) Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: Comparison of different drug interaction models. Med Mycol, 43, pp. 133-152.
189. Rex, JH, Wingard, JR and Wenzel, R. (2004) The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview. Clin Infect Dis, 39, pp. S165-S169.
190. Powers, JH (2004) Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis, 39, pp. S228-S235.
191. Bennett, JE, Dismukes, WE and Duma, RJ (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med, 301, pp. 126-131.
192. Rex, JH, Pappas, PG and Karchmer, AW (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis, 36, pp. 1221-1228.
193. Marr, KA, Boeckh, M., Carter, RA, Kim, HW and Corey, L. (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis, 39, pp. 797-802.
194. Kontoyiannis, DP, Hachem, R. and Lewis, RE (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer, 98, pp. 292-299.
195. Munoz, P., Singh, N. and Bouza, E. (2006) Treatment of solid organ transplant patients with invasive fungal infections: Should a combination of antifungal drugs be used?. Curr Opin Infect Dis, 19, pp. 365-370.
196. Baddley, JW and Pappas, PG (2005) Antifungal combination therapy: clinical potential. Drugs, 65, pp. 1461-1480.
197. Johnson, MD, MacDougall, C., Ostrosky-Zeichner, L., Perfect, JR and Rex, JH (2004) Combination antifungal therapy. Antimicrob Agents Chemother, 48, pp. 693-715.
198. Kontoyiannis, DP and Lewis, RE (2004) Toward more effective antifungal therapy: The prospects of combination therapy. Brit J Haematol, 126, pp. 165-175.
199. Sobel, JD (2004) Combination therapy for invasive mycoses: Evaluation of past clinical trial designs. Clin Infect Dis, 39, pp. S224-S227.
200. Fohrer, C., Fornecker, L. and Nivoix, Y. (2006) Antifungal combination treatment: A future perspective. Int J Antimicrobial Agents, 27, pp. S25-S30.
201. Ellepola, AN and Morrison, CJ (2005) Laboratory diagnosis of invasive candidiasis. J Microbiol, 43, pp. 65-84.
202. Lee, MK, Williams, LE, Warnock, DW and Arthington-Skaggs, BA. (2004) Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother, 53, pp. 217-224.
203. Revankar, SG, Kirkpatrick, WR and McAtee, RK (1998) Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol, 36, pp. 153-156.